Kim Forest Competitors and Similar CompaniesClear all
Kim Forest's competitors and similar companies include Lutonix, Intra-Cellular Therapies, Histocell and Pharmanutra.
 Kim Forest Kim Forest (金萬林企業股份有限公司) is a company that develops, manufactures, and sells biomedical products. |  Lutonix Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. |  Intra-Cellular Therapies Intra-Cellular Therapies develops drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the CNS. |  Histocell Histocell is a biopharmaceutical company focused on the development, manufacturing, and commercialization of medical devices, active ingredients, and cell therapy drugs for regenerative medicine. |  Pharmanutra Pharmanutra, a pharmaceutical company, engages in the research, design, development, and marketing of nutraceutical supplements and medical devices. | |
Founding Date | Founding Date 2004 | Founding Date 2007 | Founding Date 2002 | Founding Date 2011 | Founding Date 2003 |
Type | Type Public | Type Subsidiary | Type Public | Type Private | Type Public |
Tags | |||||
Locations | Locations HQ | Locations Maple Grove, US HQ | Locations New York, US HQ | Locations Derio, ES HQ Larrabetzu, ES | Locations Pisa, IT HQ Pisa, IT |
Employees | Employees N/A | Employees 10 | Employees 330352% increase | Employees 365% decrease | Employees 118 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 8.1 b | Valuation ($) N/A | Valuation ($) 589.3 m |
Financial | |||||
Revenue (est.) | Revenue (est.) NT$549.1m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $680.9m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) €115.5m (FY, 2024) |
Cost of goods | Cost of goods NT$396.2m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods €6.4m (FY, 2024) |
Gross profit | Gross profit NT$154.2m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit €110.5m (FY, 2024) |
Net income | Net income (NT$148m) (FY, 2025) | Net income N/A | Net income ($74.7m) (FY, 2024) | Net income N/A | Net income €16.6m (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 35m | Total funding raised $ 225.3m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Lutonix
HQ
Maple Grove, US
Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation.
View companyIntra-Cellular Therapies
HQ
New York, US
Employees
330
Intra-Cellular Therapies develops drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the CNS.
View companyHistocell
HQ
Derio, ES
Employees
36↓ 5% decrease
Histocell is a biopharmaceutical company focused on the development, manufacturing, and commercialization of medical devices, active ingredients, and cell therapy drugs for regenerative medicine.
View companyPharmanutra
HQ
Pisa, IT
Employees
118
Pharmanutra, a pharmaceutical company, engages in the research, design, development, and marketing of nutraceutical supplements and medical devices.
View company